Our study initially predicted the potential mechanism of LMQXM for the treatment of ADHD and verified through animal experiments that LMQXM mainly acts on DRD1 to regulate the cAMP/PKA signaling pathway to increase DA levels in the PFC and striatum to control the behavioral disorders of SHRs and is most effective at medium doses. The gene discussed is DRD1; the disease is attention deficit-hyperactivity disorder.